Ardsley Advisory Partners’s TG Therapeutics TGTX Stock Holding History

Ardsley Advisory Partners’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-185,000	Closed	-$6.16M	–	157
2021 Q3	$6.16M	Sell	185,000 -165,000	-47%	-$5.1M	0.94%	30
2021 Q2	$13.6M	Buy	350,000 +50,000	+17%	+$1.96M	1.6%	18
2021 Q1	$14.5M	Sell	300,000 -100,000	-25%	-$4.8M	1.76%	20
2020 Q4	$20.8M	Buy	+400,000	New	+$13.5M	3.42%	8

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ardsley Advisory Partners's TGTX Position: Q4 2021 in Review

Ardsley Advisory Partners sold out of TG Therapeutics (TGTX) in Q4 2021, closing a stake of 185,000 shares — an estimated $6.16M sold.

Ardsley Advisory Partners first reported a position in TGTX in Q4 2020 and held it in 4 quarters. The position peaked at $20.8M in Q4 2020. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

Ardsley Advisory Partners reported no remaining TG Therapeutics position as of Q4 2021 after selling out during the quarter.
Ardsley Advisory Partners sold 185,000 TG Therapeutics shares in Q4 2021, an estimated $6.16M.
Ardsley Advisory Partners first reported a position in TG Therapeutics in Q4 2020 and held it in 4 quarters.
Ardsley Advisory Partners's TG Therapeutics position peaked at $20.8M in Q4 2020.
194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on Ardsley Advisory Partners's 13F filing for Q4 2021, filed 14 Feb 2022.